Thiopurine monitoring in children with inflammatory bowel disease: A systematic review

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 467-476

  Konidari, Anastasia ^a   Anagnostopoulos, Antonios ^a   Bonnett, Laura J ^a   Pirmohamed, Munir ^a   El Matary, Wael ^b,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

drug monitoring; inflammatory bowel disease; thiopurine

Indexed keywords

6 METHYLTHIOINOSINE; DRUG METABOLITE; MERCAPTOPURINE; NUCLEOTIDE; RIBONUCLEOTIDE; TIOGUANINE; IMMUNOSUPPRESSIVE AGENT; PURINE DERIVATIVE;

BLOOD TOXICITY; CHILDHOOD DISEASE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; CHILD; DRUG-INDUCED LIVER INJURY; INFLAMMATORY BOWEL DISEASES; MEDICATION COMPLIANCE; METABOLISM; PROCEDURES;

CHILD; DRUG MONITORING; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; MEDICATION ADHERENCE; PURINES; TREATMENT OUTCOME;

EID: 84906499933     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12365     Document Type: Review

References (83)

1. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
2. Jakobsen C, Munkholm P, Paerregaard A, Wewer V,. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators- A population-based study. Inflamm Bowel Dis 2011; 17: 1731-1740.
3. Pearson DC, May GR, Fick GH, Sutherland LR,. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142.
4. Cuffari C, Theoret Y, Latour S, Seidman G,. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-406. (Pubitemid 26338529)
5. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA,. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915. (Pubitemid 34267273)
6. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M,. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208. (Pubitemid 46425646)
7. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ,. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 686-694. (Pubitemid 350199222)
8. Miheller P, Lakatos PL,. Thiopurines in Crohn's disease, is there something new? Expert Opin Drug Metab Toxicol 2010; 6: 1505-1514.
9. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC,. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-1122.
10. Duricova D, Pedersen N, Lenicek M, Jakobsen C, Lukas M, Wewer V, Munkholm P,. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. J Crohn's Colitis 2011; 5: 81-90.
11. Leleiko NS, Lobato D, Hagin S, Hayes C, McQuaid EL, Seifer R, Kopel SJ, Boergers J, Nassau J, Suorsa K, Shapiro J, Bancroft B,. 6-thioguanine levels in pediatric IBD patients: adherence is more important than dose. Inflamm Bowel Dis 2013; 19: 2652-2658.
12. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X,. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
13. Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA,. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-1549.
14. Yip JS, Woodward M, Abreu MT, Sparrow MP,. How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14: 514-518. (Pubitemid 351571831)
15. Gisbert JP, Gomollon F,. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-1800.
16. Aberra FN, Lichtenstein GR,. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 307-319. (Pubitemid 40313935)
17. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S,. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-342. (Pubitemid 43972901)
18. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE,. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-391.
19. Higgs JE, Payne K, Roberts C, Newman WG,. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010; 11: 177-188.
20. Elion GB, Hitchings GH, Vanderwerff H,. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 1951; 192: 505-518.
21. Lennard L,. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339.
22. Anderson RJ, Weinshilboum RM,. Phenolsulphotransferase in human tissue: radiochemical enzymatic assay and biochemical properties. Clin Chim Acta 1980; 103: 79-90. (Pubitemid 10148303)
23. Weinshilboum R,. Methyltransferase pharmacogenetics. Pharmacol Ther 1989; 43: 77-90. (Pubitemid 19199088)
24. Seidman EG,. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3: (Suppl. 1): S30-38. (Pubitemid 36395165)
25. Gilissen LP, Derijks LJ, Bos LP, Verhoeven HM, Bus PJ, Hooymans PM, Engels LG,. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2004; 16: 705-710. (Pubitemid 38901641)
26. Seksik P, Mary JY, Beaugerie L, Lemann M, Colombel JF, Vernier-Massouille G, Cosnes J,. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011; 17: 565-572.
27. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J,. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-782. (Pubitemid 41564356)
28. 8 erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103: 3115-3122.
29. Kirschner BS,. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-821. (Pubitemid 28452927)
30. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
31. handbook.cochrane.org., Higgins JPR, Green S,. Cochrane Handbook for Systematic Reviews of Intervention. 2011 Version 5.0.1.
32. National Institute for Health and Clinical Excellence Guidance: available at http://nice.org.uk/nicemedia/pdf/Appendix04qualityofcaseseriesfrompreop.pdf (last accessed 1 April 2013).
33. Cangemi G, Barabino A, Barco S, Parodi A, Arrigo S, Melioli G,. A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease. Int J Immunopathol Pharmacol 2012; 25: 435-444.
34. Gupta P, Gokhale R, Kirschner BS,. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-454. (Pubitemid 33070099)
35. Ohtsuka Y, Arai K, Aoyagi Y, Fujii T, Yamakawa Y, Ohtani K, Ikuse T, Baba Y, Inage E, Kudo T, Suzuki R, Nagata S, Shimizu T,. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol 2010; 25: 1626-1630.
36. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG,. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713. (Pubitemid 30171620)
37. Armstrong L, Sharif JA, Galloway P, McGrogan P, Bishop J, Russell RK,. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther 2011; 34: 1106-1114.
38. Tajiri H, Tomomasa T, Yoden A, Konno M, Sasaki M, Maisawa S, Sumazaki R, Shimizu T, Toyoda S, Etani Y, Nakacho M, Ushijima K, Kobayashi A,. Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion 2008; 77: 150-154.
39. Grossman AB, Noble AJ, Mamula P, Baldassano RN,. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14: 750-755. (Pubitemid 351898058)
40. Banerjee S, Bishop WP,. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. J Pediatr Gastroenterol Nutr 2006; 43: 324-330. (Pubitemid 44368187)
41. Pozler O, Chladek J, Maly J, Hroch M, Dedek P, Beranek M, Krasnicanova P,. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohn's Colitis 2010; 4: 623-628.
42. Soman S, Ashok D, Connolly SA, Cordell SJ, Taylor CJ, Campbell DI,. Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine. Drugs R D 2010; 10: 213-217.
43. Nguyen TM, Le Gall C, Lachaux A, Boulieu R,. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. Int J Clin Pharmacol Ther 2010; 48: 275-281.
44. Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS,. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 941-947. (Pubitemid 46525340)
45. Paerregaard A, Schmiegelow K,. Monitoring azathioprine metabolite levels and thiopurine methyl transferase (TPMT) activity in children with inflammatory bowel disease. Scand J Gastroenterol 2002; 37: 371-372. (Pubitemid 34194828)
46. Hyams JS, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J, Otley A, Evans J, Stephens M, Kay M, Keljo D, Pfefferkorn M, Saeed S, Crandall W, Michail S, Kappelman MD, Grossman A, Samson C, Sudel B, Oliva-Hemker M, Leleiko N, Markowitz J,. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106: 981-987.
47. Shih DQ, Nguyen M, Zheng L, Ibanez P, Mei L, Kwan LY, Bradford K, Ting C, Targan SR, Vasiliauskas EA,. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012; 36: 449-458.
48. Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J,. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-983.
49. Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH, Huang M, Hu PJ,. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2012; 24: 958-964.
50. Riello L, Talbotec C, Garnier-Lengline H, Pigneur B, Svahn J, Canioni D, Goulet O, Schmitz J, Ruemmele FM,. Tolerance and efficacy of azathioprine in pediatric Crohn's disease. Inflamm Bowel Dis 2011; 17: 2138-2143.
51. Crandall WV, Margolis PA, Kappelman MD, King EC, Pratt JM, Boyle BM, Duffy LF, Grunow JE, Kim SC, Leibowitz I, Schoen BT, Colletti RB,. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics 2012; 129: e1030-1041.
52. Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W,. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohn's Colitis 2012; 6: 588-596.
53. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, Garcia-Sanchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Munoz C, Calvo M, Benito LM, Bujanda L, Garcia-Fernandez FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Mancenido N, Algaba A, Froilan C, Cara C, Mate J, Abreu L, Gisbert JP,. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-554.
54. Stocco G, Londero M, Campanozzi A, Martelossi S, Marino S, Malusa N, Bartoli F, Decorti G, Ventura A,. Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. J Crohn's Colitis 2010; 4: 599-602.
55. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S,. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 251-257.
56. Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR,. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1301-1307.
57. Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Syriopoulou VP, Goutas N, Vlachodimitropoulos D, Anagnou NP, Roma-Giannikou E,. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. J Clin Pharm Ther 2010; 35: 93-97.
58. Hanai H, Iida T, Takeuchi K, Arai O, Watanabe F, Abe J, Maruyama Y, Oohata A, Ikeya K, Kageoka M, Miwa I, Yoshirou S, Hosoda Y, Kubota T,. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Inflamm Bowel Dis 2010; 16: 1376-1381.
59. Sheffield LJ, Irving P, Gupta A, Byron K, Macrae FA, Phillimore H, Dronavalli M, Rose R, George P, Walmsley T, Dixon B, Poole S, Dooley M, Sparrow M,. Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. Pharmacogenomics 2009; 10: 1091-1099.
60. Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E, Schwab M,. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007; 26: 217-225. (Pubitemid 46985496)
61. Reinshagen M, Schutz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, Oellerich M, von Ahsen N,. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-1314. (Pubitemid 47020987)
62. Qasim A, Seery J, Buckley M, Morain CO,. TPMT in the treatment of inflammatory bowel disease with azathioprine. Gut 2003; 52: 767. author reply 767-7.
63. Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE,. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 180-184. (Pubitemid 46175069)
64. Stocco G, Martelossi S, Barabino A, Fontana M, Lionetti P, Decorti G, Malusa N, Bartoli F, Fezzi M, Giraldi T, Ventura A,. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis 2005; 37: 940-945. (Pubitemid 44382346)
65. Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B,. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005; 21: 829-839. (Pubitemid 40477243)
66. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ,. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-670. (Pubitemid 32989203)
67. Kader HA, Wenner WJ, Jr, Telega GW, Maller ES, Baldassano RN,. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30: 409-413. (Pubitemid 30347236)
68. Dubinsky MC,. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743. (Pubitemid 39200711)
69. De Ridder L, Van Dieren JM, Van Deventer HJ, Stokkers PC, Van der Woude JC, Van Vuuren AJ, Benninga MA, Escher JC, Hommes DW,. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment Pharmacol Ther 2006; 23: 1137-1141. (Pubitemid 43779353)
70. Kamperidis N, Goodhand JR, Chowdhury FA, Koodun Y, Direzke NC, Naik S, Sanderson IR, Croft NM, Langmead FL, Irving PM, Rampton DS, Lindsay JO,. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 54: 685-689.
71. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM,. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1407-1413. (Pubitemid 39627545)
72. Hindorf U, Peterson C, Almer S,. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit 2004; 26: 673-678. (Pubitemid 39579150)
73. Bergan S, Rugstad HE, Klemetsdal B, Giverhaug T, Bentdal O, Sodal G, Hartmann A, Aarbakke J, Stokke O,. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monit 1997; 19: 318-326. (Pubitemid 28053488)
74. Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C,. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002; 24: 351-358. (Pubitemid 34553199)
75. Lopez-Martin C, Chaparro M, Espinosa L, Bejerano A, Mate J, Gisbert JP,. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol 2011; 34: 385-392.
76. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP,. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohn's Colitis 2010; 4: 546-552.
77. Gibson PR, Gearry RB,. Optimizing thiopurine therapy: more weight to the metabolite argument. J Gastroenterol Hepatol 2010; 25: 1592-1594.
78. Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C,. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 194-199.
79. Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pousette A, Almer S,. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-1431. (Pubitemid 44476786)
80. Heintz D, Patel A,. The role of thiopurine metabolites in thiopurine related toxicities in paediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: (S1): S1-127.
81. Parodi A, Arrigo S, Cangemi G, Covone A, Barambino A,. Correlation between 6-thioguanine levels and clinical response in children with inflammatory bowel disease treated with thiopurines: a preliminary single center study. Dig Liver Dis 2011; 43: (S410): 1590.
82. Colletti RB, Baldassano RN, Milov DE, Margolis PA, Bousvaros A, Crandall WV, Crissinger KD, D'Amico MA, Day AS, Denson LA, Dubinsky M, Ebach DR, Hoffenberg EJ, Kader HA, Keljo DJ, Leibowitz IH, Mamula P, Pfefferkorn MD, Qureshi MA,. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2009; 49: 297-303.
83. Goodhand JR, Tshuma N, Rao A, Kotta S, Wahed M, Croft NM, Sanderson IR, Epstein J, Rampton DS,. Do children with IBD really respond better than adults to thiopurines? J Pediatr Gastroenterol Nutr 2011; 52: 702-707.